TherapeuticsMD (TXMD) & Its Peers Critical Contrast

TherapeuticsMD (NASDAQ:TXMD) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare TherapeuticsMD to related businesses based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares TherapeuticsMD and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
TherapeuticsMD Competitors	-2,380.91%	-221.72%	-15.99%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for TherapeuticsMD and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
TherapeuticsMD Competitors	7765	13847	25696	1031	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given TherapeuticsMD’s rivals stronger consensus rating and higher possible upside, analysts clearly believe TherapeuticsMD has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares TherapeuticsMD and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	-$570,000.00	90.00
TherapeuticsMD Competitors	$3.54 billion	$3.17 billion	546.63

TherapeuticsMD’s rivals have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

TherapeuticsMD has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, TherapeuticsMD’s rivals have a beta of -4.30, indicating that their average stock price is 530% less volatile than the S&P 500.

Summary

TherapeuticsMD rivals beat TherapeuticsMD on 9 of the 13 factors compared.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.